Mark Sabag - 28 Jan 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, International Markets
Signature
/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag
Issuer symbol
TEVA
Transactions as of
28 Jan 2025
Net transactions value
$0
Form type
4
Filing time
30 Jan 2025, 16:03:40 UTC
Previous filing
07 Mar 2024
Next filing
14 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +183,169 $0.000000 183,169 28 Jan 2025 Ordinary Shares 183,169 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.